Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Q: Paragraph: Keytruda is already approved as a cost-effective treatment in melanoma and the National Institute for Health and Care Excellence also on Dec. 2 approved its use in the treatment of lung cancer patients who had started on chemotherapy, after Merck & Co cut the price further for the NHS. But trial data so far on the survival benefit of Keytruda as an initial lung cancer treatment has not been reliable enough,   according to NICE’s draft guidance, which will be subject to public consultation until 21 March. “The exact size of the overall survival gain for Keytruda compared to the current standard of care was uncertain because of the immaturity of the data,” a NICE spokeswoman said. Keytruda has proved effective in fighting non-small cell lung cancer in patients with high levels of a protein called PD-L1, which makes them more receptive to immunotherapy. The average cost of a course of treatment in Britain is around 29,000 pounds ($36,000) at the full list price but the NHS will pay less after getting a confidential discount. ($1 = 0.8042 pounds) Claim: UK rejects Merck's Keytruda as initial treatment for lung cancer.

A: Britain’s healthcare watchdog NICE, which assesses the cost-effectiveness of medical treatments, has stopped short of recommending the use by the National Health Service (NHS) of Merck & Co Inc’s immunotherapy drug Keytruda in newly diagnosed lung cancer patients, after giving the go-ahead in December for patients who had prior treatment.
****
Q: Paragraph: "Ed Stafford of Leicestershire, England walks in between trees as he walks through the Amazon jungle in Brazil in this undated handout photo. Former British army captain Stafford became on Monday the first known person to walk from the origin of the Amazon river, the world's second-longest river, to its mouth, after withstanding ""50,000"" mosquito bites, scorpion attacks and skin disease in his 859 day odyssey. REUTERS/Handout Ed Stafford, a 34-year-old from Leicestershire, England, dived into the Atlantic Ocean after taking 859 days to walk the length of the world’s second-longest river, starting at the peak of Mount Mismi in Peru in April 2008. “It’s just phenomenal to be here at the end of the journey after 2-1/2 years slogging our way through the jungle,” he told Reuters after arriving at the beach about 90 miles northeast of the Brazilian city of Belem. “It was really difficult to envisage how this was going to feel and I’m completely overwhelmed.”   Stafford briefly collapsed from exhaustion with only 52 miles of the 6,000-mile journey to go, passing out by the roadside after breaking out in a rash. “I feel slightly humbled that my system just decided to shut down so close to the finish,” he wrote on his blog at www.walkingtheamazon.com. Stafford has aimed to use the walk to raise awareness about the threats to the Amazon rain forest and its people, using a portable satellite video to blog about his trek. He had planned to complete the walk in about a year, but the journey was prolonged by floods that forced him to walk a roundabout route that was 2,000 miles longer than the 4,000-mile (6,400-km) length of the Amazon, which is exceeded in length only by Africa’s Nile river. He began the journey with fellow British adventurer Luke Collyer, but the pair had a falling out early in the trek and Stafford continued alone. He was joined in July 2008 by a Peruvian forestry worker, Gadiel Cho Sanchez Rivera, who pledged to walk with him for five days and has been with him on the walk ever since. A statement from Stafford’s media team said that the Briton had been: “wrongly accused of murder on two separate occasions, been imprisoned, had concrete stuffed in his mouth by hostile tribes people, been chased by Ashaninka Indians with bows and arrows, been stung by hundreds of wasps and watched as his guide ‘Cho’ removed a botfly from Ed’s head with superglue and a tree spine.”   It said he had endured “50,000” mosquito bites, lived on a diet of piranha fish, rice and beans, and dodged a variety of snakes, electric eels, scorpions, and ants, as well as contracting a skin-disfiguring disease. Famed British explorer Sir Ranulph Fiennes was quoted as saying in the statement that Stafford’s feat was “truly extraordinary.”   “No one has ever done this before and the pundits considered the route impossible,” he said." Claim: British man becomes first to walk Amazon length.

A: A former British army captain became on Monday the first known person to walk from the origin of the Amazon river to its mouth, after enduring “50,000” mosquito bites, attacks by hostile Indians and tropical disease in his nearly 2-1/2 year odyssey.
****
Q: Paragraph: Data from the 236-patient trial, which lasted 13 weeks and  compared the effectiveness of Cymbalta with placebos, were  presented at the annual congress of the European Federation of  Neurological Societies in Madrid. Lilly said 31 percent of patients taking Cymbalta  experienced a 50 percent reduction in pain, as measured by a  standard pain scale, compared with 19 percent of  placebo-treated patients. But significantly more patients taking Cymbalta dropped out  of the trial because of side effects, which included nausea,  dry mouth, fatigue, diarrhea, excessive sweating, dizziness and  constipation. Lilly said side effects were similar to those seen in  previous trials of Cymbalta for other conditions. Global second-quarter sales of Cymbalta, one of Lilly’s  biggest products, jumped 26 percent to $654 million, helped by  its other approved uses to treat fibromyalgia and generalized  anxiety disorder. The drug works by maximizing the presence of two messenger  chemicals in the brain, serotonin and norepinephrine. Claim: Lilly depression drug eases back pain in study.

A:
Eli Lilly and Co’s Cymbalta depression  treatment significantly reduced chronic low back pain in a  relatively small clinical trial, the company said on Monday.
****